Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Adaptive Biotechnologies, Argos deal

    Adaptive Biotechnologies Corp., Seattle, Wash. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Business: Infectious, Cancer The companies partnered to study immune responses induced by Argos AGS-003 and AGS-004 …

    Published on 6/27/2016
  • Advanced Proteome Therapeutics, Wilex deal

    Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Advanced Proteome and Wilexs Heidelberg Pharma GmbH subsidiary partnered to create antibody-…

    Published on 6/27/2016
  • Cantabio, University of Antioquia deal

    Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), Sunnyvale, Calif. University of Antioquia, Medellin, Colombia Business: Neurology Cantabio and the universitys Neuroscience Research Group will evaluate Cantabios small …

    Published on 6/27/2016
  • Celgene deal

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Celgene will provide $50 million to a newly formed consortium of four cancer centers as part of a 10-year deal to discover cancer treatments. Each institution …

    Published on 6/27/2016
  • Ciclofilin, ContraVir Pharmaceuticals deal

    Ciclofilin Pharmaceuticals Inc., San Diego, Calif. ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), New York, N.Y. Business: Infectious ContraVir acquired fellow HBV company Ciclofilin for up to $17 million in development …

    Published on 6/27/2016
  • Cipher, Edesa Biotech deal

    Cipher Pharmaceuticals Inc. (TSX:CPH;NASDAQ:CPHR), Mississauga, Ontario Edesa Biotech Inc., Markham, Ontario Business: Gastrointestinal Cipher granted Edesa rights to ASF-1096 to treat anorectal disorders. Cipher …

    Published on 6/27/2016
  • Epizyme, Genentech, Roche deal

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Roches Genentech unit and Epizyme partnered to conduct a Phase Ib…

    Published on 6/27/2016
  • Faron Pharmaceuticals, Pharmbio Korea deal

    Faron Pharmaceuticals Oy (LSE:FARN), Turku, Finland Pharmbio Korea Inc., Seoul, South Korea Business: Pulmonary Faron granted Pharmbio exclusive, Korean rights to develop and commercialize Traumakine in exchange for …

    Published on 6/27/2016
  • KalVista, Carbylan Therapeutics deal

    KalVista Pharmaceuticals Ltd., Salisbury, U.K. Carbylan Therapeutics Inc. (NASDAQ:CBYL), Palo Alto, Calif. Business: Ophthalmic Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81% …

    Published on 6/27/2016
  • Novartis, Medicines for Malaria Venture deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Medicines for Malaria Venture, Geneva, Switzerland Business: Infectious Novartis and the non-profit partnered to develop the pharmas malaria candidate KAF156. The …

    Published on 6/27/2016
  • Sequent Medical, Terumo deal

    Sequent Medical Inc., Aliso Viejo, Calif. Terumo Corp. (Tokyo:4543), Tokyo, Japan Business: Neurology Terumo will acquire fellow medical device company Sequent for $280 million and up to $100 million in development and …

    Published on 6/27/2016
  • Takeda, TB Alliance deal

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Global Alliance for TB Drug Development, New York, N.Y. Business: Infectious TB Alliance and Takeda partnered to develop compounds to treat tuberculosis. The …

    Published on 6/27/2016
  • Teva, Sagent Pharmaceuticals deal

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Sagent Pharmaceuticals Inc. (NASDAQ:SGNT), Schaumburg, Ill. Business: Neurology, Generics Teva will sell five U.S. ANDAs, including anesthetic drug …

    Published on 6/27/2016
  • UCLA, Bone Biologics deal

    University of California Los Angeles, Los Angeles, Calif. Bone Biologics Corp. (OTCQB:BBLG), Edison, N.J. Business: Musculoskeletal UCLA granted Bone Biologics an option to license exclusive, worldwide rights to use NEL…

    Published on 6/27/2016
  • Yumanity Therapeutics, New York Stem Cell Foundation deal

    Yumanity Therapeutics LLC, Cambridge, Mass. The New York Stem Cell Foundation, New York, N.Y. Business: Neurology, Gene/Cell therapy Yumanity and The New York Stem Cell Foundation partnered to generate induced …

    Published on 6/27/2016
  • Aegerion, QLT deal

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. QLT Inc. (TSX:QLT;NASDAQ:QLTI), Vancouver, B.C. Business: Ophthalmic, Endocrine/Metabolic Aegerion and QLT will merge to form newco Novelion Therapeutics Inc…

    Published on 6/20/2016
  • AstraZeneca, Aspen deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Business: Neurology AstraZeneca granted Aspen exclusive rights to commercialize AZs anesthetics portfolio …

    Published on 6/20/2016
  • Avacta, Mologic deal

    Avacta Group plc (LSE:AVCT), Heslington, U.K. Mologic Ltd., Thurleigh, U.K. Business: Diagnostic Avacta and Mologic partnered in a non-exclusive deal to develop rapid lateral flow diagnostics for clinical applications …

    Published on 6/20/2016
  • Boehringer Ingelheim, Harvard deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Harvard University, Cambridge, Mass. Business: Pulmonary, Renal, Hepatic Boehringer and the universitys Harvard Stem Cell Institute partnered to discover treatments for …

    Published on 6/20/2016
  • Eleven Biotherapeutics, Roche deal

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Ophthalmic Eleven granted Roche exclusive, worldwide rights to develop and commercialize EBI-031, a …

    Published on 6/20/2016
  • EnBiotix, Mayo Clinic deal

    EnBiotix Inc., Boston, Mass. Mayo Clinic, Rochester, Minn. Business: Infectious EnBiotix and Mayo Clinic partnered to develop EnBiotixs EPP-001. The product, an engineered bacteriophage that uses customized phages …

    Published on 6/20/2016
  • Innovent Biologics, Adimab deal

    Innovent Biologics Inc., Suzhou, China Adimab LLC, Lebanon, N.H. Business: Antibodies Adimab and Innovent expanded a 2013 deal to use Adimabs yeast-based antibody discovery technology. Under the expanded deal, Adimab …

    Published on 6/20/2016
  • Lucideon, Skyepharma deal

    Lucideon Ltd., Staffordshire, U.K. Skyepharma plc (LSE:SKP), London, U.K. Business: Neurology, Drug delivery Skyepharma licensed exclusive rights to use Lucideons iCRT-deter technology to develop an abuse-deterrent oral…

    Published on 6/20/2016
  • Merck, Innovative Targeting Solutions deal

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Innovative Targeting Solutions Inc., Burnaby, B.C. Business: Antibodies Innovative Targeting Solutions said it partnered with Merck to discover biologic therapeutics against…

    Published on 6/20/2016
  • Mesoblast, Teva deal

    Mesoblast Ltd. (ASX:MSB;NASDAQ:MESO), Melbourne, Australia Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cardiovascular Teva returned rights to Mesoblasts mesenchymal precursor cell (MPC…

    Published on 6/20/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993